logo
GE2025: Why Red Dot United's scientists Dr Syed Alwi Ahmad and Dr David Foo could be game-changers in Nee Soon

GE2025: Why Red Dot United's scientists Dr Syed Alwi Ahmad and Dr David Foo could be game-changers in Nee Soon

SINGAPORE: Red Dot United (RDU) has unveiled its slate for Nee Soon Group Representation Constituency (GRC) in the upcoming elections, featuring a powerhouse lineup: Secretary-General Ravi Philemon, Chairman Dr David Foo, cybersecurity expert Sharon Lin, strategist Pang Heng Chuan, and physicist Dr Syed Alwi Ahmad. But who exactly is the physicist with a heart for the community?
Meet Dr Syed Alwi Ahmad, a theoretical physicist who has spent years studying one of the most profound mysteries of the universe: black holes. These cosmic giants are so powerful that nothing—not even light—can escape their pull, but what truly happens to the matter and information that crosses the point of no return?
That's the question Dr Ahmad set out to answer in his research, blending the abstract world of quantum mechanics with real questions about what it means to lose—whether it's data, matter, or trust. Today, he's bringing that same curiosity and integrity to the political arena. What Dr Syed Alwi Ahmad did
Dr Ahmad's research zeroed in on fermions—the tiniest building blocks of matter, like electrons and neutrinos. These are particles that obey some of the strictest laws in nature, and they're essential to everything that exists.
To study them, he used a tool called Quantum Field Theory—imagine applying chemistry's periodic table not to elements, but to energy. It's a way of understanding how particles form, move, and interact with forces in the universe.
However, instead of applying this in normal space, Dr Ahmad did something more ambitious: He studied how these matter particles behave near and inside black holes. What he found
Here's where things get really fascinating.
In ordinary space, quantum fields—which describe how particles behave—are smooth and continuous, but Dr Ahmad found that when you approach a black hole, these fields for fermions don't stretch across like they should. Instead, they cut off at the event horizon—the invisible boundary beyond which nothing can return.
Imagine watching a movie, but halfway through, the screen goes black. You can still hear the sound, but you can't follow the story anymore. That's what's happening at a black hole's edge. The 'story' of the object—its identity, its data—gets silenced, and all we see is thermal static.
Because of this, the radiation coming from black holes looks like random heat—not a message, not a pattern, just noise. Why this matters
This research gives us one possible answer to the age-old question: What happens to the past when it falls into a black hole?
Dr Ahmad's work suggests that the information may not come back—not in any readable, recoverable way. That would mean black holes don't just eat matter—they erase memory.
Or, it could mean that we're still missing a major piece of the puzzle and that our understanding of the universe needs to evolve. A Singaporean at the edge of space-time
What's truly inspiring is that this work didn't just come from a top Ivy League lab—it came from a Singaporean physicist. Dr Ahmad's journey shows that world-changing ideas can come from anywhere, even the heartlands of Yishun.
He approached one of the most difficult puzzles in physics not with sci-fi drama, but with cold, clear mathematics—and concepts most of us first encounter in O-Level physics and chemistry: energy, particles, and the conservation of information.
His work doesn't just inspire scientists—it inspires young Singaporeans to ask bold questions, dream bigger, and know that the horizon of discovery is open to them too.
Dr Ahmad has said:
'To truly understand what people are going through, you need both a microscope and a telescope — to see the fine details of daily struggle, and the wide horizon of possibility.'
It's this same mindset he brings to politics.
He believes unity doesn't mean conformity. It means listening deeply, lifting others, and leading with dignity. Only then, he says, can we bring out the best in Singapore—not by silencing difference, but by making space for it. What about the chemist who went from lab coats to the ballot box?
Dr David Foo, chairman of RDU and the second scientist on the party's Nee Soon GRC slate, isn't your typical politician. He's a chemist, an educator, and a staunch advocate for civic awareness—all rolled into one.
As Singapore heads toward GE2025, Dr Foo is once again stepping into the political arena, but he doesn't come armed with slogans alone. He brings a career built on inquiry, service, and reform. A Scientist first: Chemistry at his core
Dr Foo earned his PhD in chemistry from the University of Idaho, laying the groundwork for a career that has spanned continents and disciplines.
In the early stages of his career, he worked in high-level laboratories in the United States, later returning to Singapore where he became one of the founding scientists of the Institute of Chemical and Engineering Sciences (ICES). His expertise also led him to Johnson & Johnson's regional research centre, where he contributed as part of their technical staff.
A major highlight? Dr Foo became the first Singaporean to be awarded the Glenn T. Seaborg Fellowship at the prestigious Los Alamos National Laboratory in the US—a top-tier recognition in the field of nuclear and analytical chemistry. Championing science education
However, Dr Foo didn't stay behind the lab bench.
Believing strongly in the power of youth education, he founded Science Ventures Learning Hub, a platform dedicated to making science more interactive, engaging, and accessible to students.
He played a significant role in Singapore's National Science Challenge, helping design chemistry challenges beyond rote learning—challenges that inspired curiosity, creativity, and critical thinking in young minds. From Political Awareness to Policy Making
Dr Foo's political journey began in 2001, when he co-founded Think Centre, one of Singapore's earliest and boldest independent civic research organisations. At a time when political discourse in Singapore was still tentative, his move into civil society was both visionary and courageous.
He contested in Jurong GRC during the 2015 General Election under the Singaporeans First party and later joined RDU, where he now plays a leadership role. Today, he is contesting Nee Soon GRC as part of RDU's diverse and forward-looking team—alongside figures like secretary-general Ravi Philemon and theoretical physicist Dr Syed Alwi Ahmad. Science meets policy
Dr Foo represents the rare convergence of scientific precision and policy vision.
Whether he's discussing climate action, energy sustainability, or public health, he brings to the table a calm, methodical approach rooted in data and evidence, but just as importantly, he pairs that objectivity with a belief in civic empowerment and transparency.
To him, policymaking isn't about political theatre—it's about making sense of complex systems and finding solutions that work. Why it matters
In a political landscape often shaped by bureaucratic inertia and risk-averse leadership, Dr Foo is a breath of fresh air. He reminds us that public service doesn't just belong to lifelong politicians. It belongs to scientists, teachers, and ordinary citizens with a commitment to truth and change.
As Singaporeans head to the polls, figures like Dr David Foo raise a powerful question:
What kind of leadership do we want?
One that simply manages the status quo—or one that dares to innovate, educate, and elevate?
Stay tuned to The Independent for more deep dives and human stories behind the headlines—as we journey together toward Singapore's next General Election.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong
Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong

Straits Times

time6 days ago

  • Straits Times

Mirxes, Singapore's billion-dollar biotech firm led by life sciences scholar Zhou Lihan, lists in Hong Kong

Mirxes CEO Dr Zhou Lihan, his wife Yeap Su Phing, parents and two children at the Hong Kong Stock Exchange in Central after the Singapore biotech firm launched its IPO on May 23. PHOTO: MIRXES – Singapore has produced its first billion-dollar biotechnology start-up, 25 years after it began formally building its life sciences industry. Mirxes, which invented and produces the world's first blood test kit to detect early stage gastric cancer, is helmed by Dr Zhou Lihan, a naturalised Singaporean from the country's maiden batch of life sciences graduates. He arrived on the Lion City's shores as a wide-eyed 15-year-old PRC (People's Republic of China) scholar, navigating life and studies in a foreign country. Today, the 42-year-old is chief executive officer and co-founder of Mirxes (pronounced 'm'raek'sis'). It is the first South-east Asian biotech start-up to achieve a valuation of more than US$1 billion (S$1.29 billion), when on May 23 it launched its initial public offering (IPO) on the Hong Kong Stock Exchange (HKEX). The company's market capitalisation is HK$8.29 billion, or US$1.06 billion. It has been trading around HK$30 per share, up 28 per cent from its listing price of HK$23.30. It is also South-east Asia's first biotech firm to list on HKEX. The microRNA-based cancer-detection start-up, which was spun out of Singapore's public sector R&D agency A*Star in 2014, has yet to become a household name in the country. But it is already a big player in the regional biotech industry. Now, the company has reached a critical level in its development where it can build on its success only by leveraging on an expansive fund-raising platform with a mature base of investors familiar with the industry. That is why, instead of listing in Singapore, Mirxes opted to do so first in Hong Kong, Dr Zhou told The Straits Times. He does not, however, discount the possibility of Mirxes listing in Singapore eventually. Dr Zhou's life story in the Republic tracks closely with some of the country's strategic economic policies over the years. 'I left China in 1998 after learning, through the Suzhou-Singapore Industrial Park project, about the opportunity to take on a scholarship to come to Singapore,' the Suzhou-born Dr Zhou told ST in an unmistakably Singaporean accent. Dr Zhou (second from left) with his fellow PRC scholars studying in Singapore's Anglican High School in 1998. PHOTO: COURTESY OF ZHOU LIHAN The project was launched in 1994 for China to adapt the Republic's development experiences to its own context, and for Singapore to develop an external wing to its economy. The PRC scholarship system is a Singapore Government-sponsored scheme for top Chinese teenage students since the 1990s, aimed at having them eventually contribute to economic development and potentially set down roots in the country . Finding love at NUS After going through the local education system at Anglican High School and Temasek Junior College, Dr Zhou enrolled at the National University of Singapore (NUS) in 2003, among the first batch of life sciences students. The life sciences programme was introduced as part of a government initiative in 2000 to develop the Republic into a regional biomedical hub. 'Because I spent most of my formative years in Singapore, all my friends and family are in Singapore. I even met my wife in NUS on shuttle bus A2, heading from the arts faculty to (university hostel) Prince George's Park,' Dr Zhou recalled with a laugh. Dr Zhou (top row, second from left), with Associate Professor Too Heng-Phon (far right) and fellow researchers from Prof Too's lab during their university days in 2008. PHOTO: COURTESY OF ZHOU LIHAN His wife, a Malaysian-born Singaporean, was an NUS arts student whom he got to know better in the students' union , he explained. They have a son and a daughter, aged eight and three, respectively. The family, including Dr Zhou's parents who have also moved from Suzhou to Singapore , were at HKEX in the central business district to witness Mirxes' IPO launch on May 23. Mirxes' history dates back to Dr Zhou's days at NUS, where he obtained his PhD in biochemistry and molecular biology at the Yong Loo Lin School of Medicine in 2012. During his PhD studies, he, fellow scientist Zou Ruiyang and their mentor, Associate Professor Too Heng-Phon, developed the technology to detect microRNA (micro ribonucleic acid), the smallest genetic material ever found in living things. Dr Zhou with his mentor, Prof Too, on his graduation day in 2007. PHOTO: COURTESY OF ZHOU LIHAN Their research, which the trio took with them to A*Star when they joined the agency in 2010, proved so ground-breaking that they set up an enterprise three years later with the agency's support and a government grant to commercialise their technology. Thus, Mirxes was born: a three-person start-up with Dr Zhou as CEO, Dr Zou as chief technology officer, and Prof Too as chief scientific adviser, aimed at developing an accurate, affordable and easily accessible early detection system for various cancers and other diseases. In the decade since, Mirxes has grown into a 350-strong company with a presence in China, Japan, Malaysia, the Philippines and the United States, and partnerships with global biotech giants including Johnson & Johnson and Pfizer. Dr Zhou (left) and Mirxes' co-founder, Dr Zou Ruiyang, at the biotech startup in the initial years after it spun off from A*Star. PHOTO: MIRXES The firm's flagship invention, GastroClear, in 2019 became the world's first molecular blood test approved for early detection of gastric cancer in high-risk populations. It was developed in close collaboration with the Singapore Gastric Cancer Consortium. The test – available in Singapore for less than $150 at public hospitals or around $250 in private clinics – is less expensive and invasive than an endoscopy, the traditional diagnostic procedure for stomach cancer, which can cost between $400 and $3,000. GastroClear has an 87 per cent accuracy, better than any other blood-based tests for the detection of gastric cancer. Patients who test positive are recommended to undergo an endoscopy for more specific results. The test is less expensive and invasive than an endoscopy, the traditional diagnostic procedure for stomach cancer, which can cost between $400 and $3,000. PHOTO: NATIONAL UNIVERSITY HEALTH SYSTEM Listing in Hong Kong Months of careful consideration preceded Mirxes' decision to list in Hong Kong over Singapore. Ultimately, it came down to two key factors. 'Firstly, our flagship product GastroClear is focused on stomach cancer, a very Asian disease,' Dr Zhou said. 'China alone accounts for half of all stomach cancer cases worldwide.' The Hong Kong platform provides a gateway into mainland China, the biggest market not just for stomach cancer tests, but also for the scale and speed of cancer clinical trials to accelerate the firm's research and development efforts. 'So listing in (the Chinese territory of) Hong Kong makes sense, because the investors here will understand our product's value to them.' Secondly, he added, HKEX's dedicated biotech listing regime has built up an investor base that 'understands how to look at biotech firms' financials without getting scared off'. Mirxes is still in the red, reporting net losses exceeding US$92 million for 2024 – 30 per cent more than the previous year. It is already generating revenue, although the US$20 million it reported for 2024 is a 16 per cent drop from that in 2023. 'People get worried that Mirxes is losing money,' Dr Zhou said. 'But if we want to be competitive globally, we have to invest in R&D and innovation. But that's something that our South-east Asian investor base is not yet familiar with.' HKEX's investors, on the other hand, are no strangers to promising yet still-loss-making start-ups. Hong Kong in 2018 started allowing yet-to-be-profitable biotech firms to list on its main board under the exchange's Chapter 18A regulations, to attract companies in cutting-edge industries. Since then, more than 70 such firms – which would otherwise not have qualified to list – have launched their IPOs in the city, gaining access to much-needed funds to grow their fledgling technologies and innovations . Mirxes CEO Dr Zhou Lihan (right) with a Hong Kong Stock Exchange representative at the IPO ceremony in Hong Kong on May 23. PHOTO: MIRXES The 18A rules recognise these start-ups' potential for growth, granting them access to capital as long as they have one core product past the concept phase, HK$1.5 billion in expected market value, and two years of financial records, among other criteria. In Asia, biotech start-ups that have yet to bring in revenue can also choose to list on subsidiary boards that cater to such firms, like China's ChiNext, Singapore's Catalist and Korea's Kosdaq. But the drawbacks include lower trading volumes and hence lower funding , and less visibility . Rebuilding ties in China HKEX's listing reforms, like Chapter 18A, have over the years opened new pathways for a broader range of companies around the world to raise funds in the city. It is on track to be the world's top IPO destination by the end of 2025, according to Swiss investment bank UBS. Its IPO market has raised HK$76 billion so far in 2025, more than seven times that in the same period a year ago, Financial Secretary Paul Chan said on May 25. The city is further cementing its status as a leading fund-raising hub for the tech and biotech sectors. In early May, it set up a scheme to streamline the IPO process for such firms, offering them 'a more efficient pathway' to listing and allowing them to file confidentially to avoid drawing competitors' attention. But some companies seeking a Hong Kong listing may still face a lengthy approval process from the China Securities Regulatory Commission, under rules introduced in March 2023 that also pertain to firms with principal business operations in mainland China. Mirxes, which has laboratories in Hangzhou, filed to list in Hong Kong in July 2023. One of Mirxes' laboratories in Singapore. It has a presence in China, Japan, Malaysia, the Philippines and the United States. PHOTO: MIRXES Dr Zhou said that while his China background is 'definitely helpful' in bringing Mirxes to the world's second-biggest economy, 'honestly, I had to rebuild all my connections there as I had left China as a secondary school student'. These days, he is a 'weekend dad', travelling around mainland China, Hong Kong and South-east Asia for work and seeing his family in Singapore only on weekends. 'Most people – my parents included – will not be able to fully comprehend the technical details of what we do at Mirxes,' Dr Zhou said. The firm will allocate some of its IPO funds to promote awareness and the use of GastroClear in China and South-east Asia. The cash will also fund ongoing research into its colorectal and multi-cancer detection tests, among other plans. Reflecting on Mirxes' journey from fledgling start-up to IPO, Dr Zhou said the listing 'would not have been possible without the Singapore Government's strong support and consistent investment in life sciences over the years'. 'It proves a point that our Singapore technologies and companies are as good, if not better, than others,' he said. 'But we tend to be a little too humble, and not as patient .' The vibrant ecosystem of biotech firms in Boston or San Francisco, for example, was built up over 50 years, the CEO noted. 'In Singapore, we started only some 20 years ago … We are reaching a point where we should see more companies like Mirxes taking their next steps .' Dr Zhou hopes Mirxes' IPO will go a long way in enhancing the company's global credibility. 'If the public sees that this biotech firm has been vetted, has gone public, and everything about it is transparent and fully disclosed, that will add a layer of trust,' he said. 'And in the healthcare business, trust is very important.' Magdalene Fung is The Straits Times' Hong Kong correspondent. She is a Singaporean who has spent about a decade living and working in Hong Kong. Join ST's Telegram channel and get the latest breaking news delivered to you.

Home Team humanoid robots to be deployed by mid-2027, $100m to be invested: Josephine Teo, Singapore News
Home Team humanoid robots to be deployed by mid-2027, $100m to be invested: Josephine Teo, Singapore News

AsiaOne

time26-05-2025

  • AsiaOne

Home Team humanoid robots to be deployed by mid-2027, $100m to be invested: Josephine Teo, Singapore News

SINGAPORE — Home Team officers will work together with their robot counterparts when the latter are deployed as soon as by mid-2027. The humanoid robots will perform high-risk tasks such as firefighting, hazardous materials (hazmat) operations, and search-and-rescue missions. Initially, the robots will be controlled remotely by human operators, but are expected to be powered by artificial intelligence (AI) and deployed autonomously from 2029. During autonomous deployment, AI will allow the machines to respond to different scenarios, with humans supervising and intervening only when necessary. On May 26, four of these robots, which are being developed by the Home Team Science and Technology Agency (HTX), were showcased at the opening of the AI TechXplore exhibition. The two-day science and technology exhibition, held at Fusionopolis One, highlights HTX's efforts to leverage AI to enhance Home Team operations. The exhibition was held alongside the HTX career fair, Careers@HTX. Three of the robots on display are about 1.7m-tall, while the fourth is half a metre shorter. HTX engineers built an exo-suit for operators to wear to control the smaller robot. Information from the exo-suit is transmitted to the robot, allowing it to replicate the operator's movements in real time. The operator also wears a virtual reality headset that allows him or her "to see" through the robot's cameras to perform various tasks. The event also saw the launch of Phoenix, HTX's large language model (LLM) that was trained in-house and is familiar with the Singaporean and Home Team context, conversant in all four official languages in Singapore. Phoenix will be the brain of the Home Team's AI capabilities. Speaking at the event, Minister for Digital Development and Information Josephine Teo said $100m will be invested into the new Home Team Humanoid Robotics Centre (H2RC), which will be dedicated to developing humanoid robots intended for public safety. It is the first such facility in the world, and is slated to become operational by mid-2026. It will feature zones for data collection, AI model training and robotics development, and will house high-performance computing resources. Teo said: "Criminals are exploiting technology in ways never before imagined. As a result, law enforcement agencies, too, must understand how the technologies are being misused. "But that on its own is not going to be enough. We must also have the capabilities to use the technology to fight crime, to do better for our people." The minister added that H2RC will push the frontiers of AI. She said: "This initiative marks a fundamental shift in the development of robotics capabilities in the Home Team — from today's pre-programmed systems to tomorrow's Gen AI-powered intelligent platforms that can move, think, and act autonomously to protect and save lives." Ang Chee Wee, Chief AI Officer and Assistant Chief Executive (Digital and Enterprise) at HTX, said the facility is a significant step forward for HTX's AI strategy, as advances in robotics open up new possibilities for frontline support. He said: "By putting humanoid robots in realistic environments, we can evaluate how AI can complement our officers, enhance safety, and support the long-term operational needs of the Home Team." The Home Team has used multiple robots over the years, with one of the earliest iterations of a patrol robot being used at large-scale events in 2018. The pace of development and deployment quickened after the formation of HTX in end-2019, which helped develop the Rover-X robotic dog and the more recent cyborg cockroaches sent to Myanmar to assist in search-and-rescue efforts. Drones are now also a common sight at large public events such as the recent political rallies, and help with both crowd control and other police operations. The advent of humanoid robots looks set to further shape the security scene in Singapore, with security provider Certis announcing on May 19 that it too has received its first humanoid robot. Dr Daniel Teo, director of Robotics, Automation and Unmanned Systems Centre of Expertise at HTX, said he was looking forward to further harnessing the potential of robots for the Home Team. He said: "Public safety operations require robotic systems that are adaptable and resilient. These AI-driven robots have a huge potential to enhance the safety and effectiveness of frontline officers." [[nid:718333]] This article was first published in The Straits Times. Permission required for reproduction.

Singaporean writer Ng Yi-Sheng's short story in the running for Japanese literary prize
Singaporean writer Ng Yi-Sheng's short story in the running for Japanese literary prize

Straits Times

time18-05-2025

  • Straits Times

Singaporean writer Ng Yi-Sheng's short story in the running for Japanese literary prize

Singaporean author and poet Ng Yi-Sheng's literary work The World's Wife has been shortlisted in the Best Translated Short Story category of Japan's Seiun Awards. PHOTO: ST FILE SINGAPORE – Singaporean writer Ng Yi-Sheng has been shortlisted for a Japanese science fiction award. The 44-year-old two-time winner of the Singapore Literature Prize has been given a nod in the Best Translated Short Story category of Japan's Seiun Awards , which honours the best in original and translated works of science fiction. His shortlisted work is the 1,060-word short story The World's Wife, translated by Kujirai Hisashi. The story, originally published in December 2023 in the science fiction and fantasy magazine Clarkesworld, tells the tale of a woman whose husband's dead body forms a new planet in space. Ng will face stiff competition, going up against The Three-Body Problem's (2008) famed Chinese author Liu Cixin for her short story Time Immigrant, and the American author of the Hugo Award-winning Wayfarers series (2014 to 2021) Becky Chambers, who was nominated for her solarpunk novella A Psalm for the Wild-Built. The Seiun Awards (which means the Nebula Awards, not to be confused with the American science fiction award of the same name) is often described as the Japanese equivalent of the Hugo Awards. The annual Hugo Awards, which honours science fiction or fantasy works, are given out at the World Science Fiction Convention and chosen by its members. In a similar vein, the Seiun Awards are given out at the Japan Science Fiction Convention and picked by its participants via voting. On May 18, Ng posted the news on Facebook and admitted he felt 'intimidated' to be nominated alongside Liu. He said: 'I've been shortlisted for the 2025 Seiun Awards... first time I've ever been on the shortlist (not longlist) for any international affair, so I'm thrilled.' 'I've got this honour less due to my own merit than due to the kindness of friends and the talent of translators,' he added. Aside from The World's Wife, the poet and activist has written Lion City, a short story collection of speculative fiction which won the Singapore Literature Prize in 2020. His debut poetry collection Last Boy won the same prize in 2008. Voting for the awards runs until June 30, and the winners will be announced in mid-July, with the awards ceremony held in conjunction with the Japan Science Fiction Convention on Aug 31. Join ST's Telegram channel and get the latest breaking news delivered to you.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store